Effects of Interleukin-6 Dysregulation in a Mouse Model of Alzheimer’s Disease: Unraveling Complexity Beyond Amyloidosis
Cells · 2026
DOI: 10.3390/cells15211921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Carla Canal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Animal Physiology Unit, Department of Cell Biology, Physiology and Immunology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Bellaterra,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Interleukin-6, Amyloidosis. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Economía y Competitividad, Fondo Europeo de Desarrollo Regional, Ministerio de Ciencia, Innovación y Universidades.
Themen: Demenz
Abstract (Originalsprache)
Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in neuroinflammation and Alzheimer’s disease (AD) pathophysiology, but its contribution to the phenotype associated with amyloid precursor protein (APP) overexpression remains unclear. Here, we investigated the effects of systemic IL-6 deficiency in Tg2576 mice by assessing survival, physiological parameters, behavior, learning and memory, APP/amyloid-β (Aβ)-related pathology, and gliosis in young and aged male and female mice. In this specific cohort of animals, Tg2576 mice exhibited reduced survival and body weight, together with age- and sex-dependent alterations in behavioral and cognitive parameters. Notably, despite increased circulating Aβ40 and Aβ42, Aβ40 and Aβ42 were undetectable in the brain, and amyloid plaques were absent in Tg2576 mice compared with plaque-positive control mice. IL-6 deficiency partially rescued several of these phenotypes, particularly in females. Thus, the APP overexpression-associated phenotype observed here occurred in the absence of detectable cerebral amyloidosis, highlighting that APP overexpression-associated alterations can manifest independently of amyloid plaque deposition. Together, our findings underscore the complexity of AD pathogenesis and emphasize the multifaceted nature of IL-6 in both physiological and neurodegenerative processes, particularly in the context of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Animal Physiology Unit, Department of Cell Biology, Physiology and Immunology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
- Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
- Institute for Research in Biomedicine (IRB Barcelona), 08028 Barcelona, Spain.
- Centre for Physical Activity Research (CFAS), Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
ORCID-Profile: Paula Sanchis, Juan Hidalgo
Förderung
- Ministerio de Economía y Competitividad
- Fondo Europeo de Desarrollo Regional
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Ciencia e Innovación
- Ministerio de Economía y Competitividad y Fondo Europeo de Desarrollo Regional
- Ministerio de Ciencia, Innovación y Universidades y Fondo Europeo de Desarrollo Regional
Zitieren
APA
Canal, C., Aguilar, K., Comes, G., Molinero, A., Giralt, M., Sanchis, P., & Hidalgo, J. (2026). Effects of Interleukin-6 Dysregulation in a Mouse Model of Alzheimer’s Disease: Unraveling Complexity Beyond Amyloidosis. Cells. https://doi.org/10.3390/cells15211921
Vancouver
Canal C, Aguilar K, Comes G, Molinero A, Giralt M, Sanchis P, et al. Effects of Interleukin-6 Dysregulation in a Mouse Model of Alzheimer’s Disease: Unraveling Complexity Beyond Amyloidosis. Cells. 2026. doi:10.3390/cells15211921
BibTeX
@article{Canal2026,
author = {Canal, Carla and Aguilar, Kevin and Comes, Gemma and Molinero, Amalia and Giralt, Mercedes and Sanchis, Paula and Hidalgo, Juan},
title = {Effects of Interleukin-6 Dysregulation in a Mouse Model of Alzheimer’s Disease: Unraveling Complexity Beyond Amyloidosis},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15211921}
}
EUVIMED